Weight & Metabolic
Is 'Food Noise' a Real, Measurable Thing?
The short answer
It started as a patient-coined term with no formal clinical definition, and researchers are still building the tools to measure it. A 550-person retrospective survey using a new 5-item Food Noise Questionnaire found scores roughly halved after starting semaglutide. A small controlled lab study found the same drop after 6 months, alongside a measurable shift in sweet-taste detection. A validated, decades-older instrument — the Control of Eating Questionnaire — shows durable reductions in food cravings through two years in a large randomized trial. But a small real-world cohort using yet another validated scale found cravings essentially unchanged. The underlying construct is real enough that multiple research groups are now racing to standardize how to measure it — which also means, as of today, there isn't one settled way to measure it.
Quick answers
- What is it?
- "Food noise" is a patient- and clinician-coined term for constant, intrusive thoughts about food and cravings; it has no formal clinical definition, and researchers are still building tools to measure it.
- Why are people interested in it?
- Many people taking semaglutide or tirzepatide report their mental preoccupation with food quiets down, and readers want to know whether that's a real, measurable effect or just a marketing narrative.
- What has actually been studied?
- A 550-person retrospective online survey using a new 5-item questionnaire, a small controlled lab study comparing pre-use, 1-month, and 6-month GLP-1 users, a 2-year randomized trial (STEP 5) using a validated craving questionnaire, a small 28-person real-world cohort, and an earlier crossover trial.
- How strong is the evidence?
- Mixed and emerging: several studies using different tools found reduced food noise or cravings after starting a GLP-1, but the main Food Noise Questionnaire is new and not yet fully validated, and one small real-world cohort found no significant overall change in cravings.
- What don't we know yet?
- Whether the Food Noise Questionnaire is fully validated, why different craving instruments disagree, the underlying brain mechanism in humans, whether food noise reduction predicts long-term weight outcomes, and what happens to food noise after stopping treatment.
- Where can I read the original research?
- Sources at the bottom of this page: Hayashi D, Edwards C, Emond JA, et al., Nutrients, 2023; and Arnaut T, Duncan S, Faurby M, et al., Advances in Therapy, 2026.
The short answer: "Food noise" isn't a term that came from a lab — it came from patients and clinicians describing what changed when they started a GLP-1, and researchers are now scrambling to catch up with tools to measure it. A 550-person retrospective survey using a newly built 5-item questionnaire found self-reported scores roughly halved after starting semaglutide. A small controlled study using the same tool found a significant reduction after 6 months, alongside a measurable shift in how strongly people detected sweetness. A much older, validated instrument for food cravings shows durable improvement through two years in a major randomized trial. But a small real-world cohort using yet another validated craving scale found no significant overall change. The phenomenon has real, converging evidence behind it — but the measurement science is young, inconsistent, and still being built in real time.
What the research shows
Where the term came from
A 2023 narrative review in Nutrients was among the first academic attempts to formalize what "food noise" meant. The authors noted that as GLP-1 receptor agonists like semaglutide became widely used for weight management, "anecdotal reports from patients and clinicians alike" described a reduction in rumination and obsessive preoccupation about food. Rather than measure food noise directly — no validated tool existed yet — the paper proposed a conceptual model (the Cue-Influencer-Reactivity-Outcome, or CIRO, framework) built on an existing research area called food cue reactivity, to give future studies a scaffold to work from.
The first purpose-built surveys
By 2026, a dedicated instrument existed: the 5-item Food Noise Questionnaire (FNQ), scored 0 to 20. The INFORM survey applied it retrospectively to 550 US adults who had been using injectable semaglutide for weight management, mostly for 4 months or longer. Participants recalled their food noise level before starting treatment and rated it again as of the survey. Median recalled pre-treatment FNQ score was 13 (interquartile range 10–16); the post-treatment median was 6 (IQR 3–10) — an overall median drop of 5 points. Agreement with statements indicating the presence of food noise fell from a range of 47–63% before treatment to 15–20% after. The reduction held up consistently across subgroups defined by treatment duration and starting BMI, and 83% of respondents reported treatment satisfaction. The obvious limitation: this relied on people recalling how they felt before starting a drug they were now taking, months or years later — a design vulnerable to recall bias in the direction the survey was measuring.
A controlled study adds a physical signal
A 2026 cross-sectional study out of Purdue took a more controlled approach, comparing three groups of adults with obesity: people eligible for GLP-1 treatment but not yet using one, 1-month users, and 6-month users. Using the same Food Noise Questionnaire alongside laboratory taste and craving assessments, the study found FNQ scores were significantly lower in the 6-month group than in the pre-use group (P=.026), alongside lower cue responsivity, food cravings, food reward, and measured energy intake. It also found a specific sensory shift: both the 1-month and 6-month GLP-1 groups needed a more concentrated solution to detect sweetness than the pre-use group did (P=.0078 and P=.0024, respectively), while other taste qualities, smell, and most other chemosensory measures were largely unchanged. That's a genuinely novel, physiologically measured finding — not just a self-report.
A validated craving scale, over a much longer timeline
Separately from "food noise" specifically, a validated instrument called the Control of Eating Questionnaire (CoEQ) has tracked food cravings in GLP-1 trials for years. In STEP 5 — a 2-year randomized trial of semaglutide 2.4 mg — Craving Control and Craving for Savory domain scores improved significantly with semaglutide versus placebo at weeks 20, 52, and 104 (P<0.01 at every timepoint), and improvements in craving scores correlated with weight loss. An earlier, smaller crossover trial of the same drug found less hunger and fewer food cravings alongside a 24% reduction in total ad libitum energy intake across a day of meals.
The finding that complicates the picture
Not every study lines up. The CRAVE study, a small 2026 real-world cohort of 28 adults starting semaglutide or tirzepatide without structured nutrition support, used a different validated tool — the Food Cravings Inventory-III — and found food cravings were unchanged overall after 24 weeks, even as participants lost significant weight and body fat. The one nuance: people who started with higher baseline cravings saw larger reductions (r=−0.69, P<0.001), suggesting the effect may be concentrated in people who had the most food noise to begin with, and diluted to nothing in a small sample that included people who didn't.
What we don't know yet
Whether the Food Noise Questionnaire itself is fully validated. It's new, used in only a couple of published studies so far, and its psychometric properties — reliability, how it compares across populations — are still being established.
Why different craving instruments give different answers in different studies. STEP 5's validated CoEQ showed durable improvement over two years; CRAVE's validated Food Cravings Inventory-III showed no significant overall change over six months. Whether this reflects the instruments, the populations, or genuine biological variability isn't resolved.
The underlying brain mechanism, in humans. Proposed models link food noise reduction to reduced activity in brain networks involved in food-related rumination, but this rests on preclinical and indirect evidence — no published human neuroimaging study has directly confirmed it as the mechanism.
Whether food noise reduction predicts long-term outcomes. No study has yet tested whether the size of someone's food noise drop predicts how much weight they lose, keep off, or regain after stopping treatment.
How food noise behaves after stopping treatment. No published study has tracked whether food noise returns to baseline, and on what timeline, once someone stops a GLP-1 — a question that matters given how central appetite regulation is to the discontinuation-and-regain pattern seen with these drugs.
Sources
- Hayashi D, Edwards C, Emond JA, et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients, 2023;15(22):4809. DOI
- Arnaut T, Duncan S, Faurby M, et al. Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey. Advances in Therapy, 2026;43(8):3649–3659. DOI
- Rutigliani G, Mattes RD. The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior. Physiology & Behavior, 2026;115486. DOI
- Wharton S, Batterham RL, Bhatta M, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity, 2023;31(3):703–715. DOI
- Babazadeh D, Therrien S, Fitch AK, Steinberg FM. Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study. Obesity Pillars, 2026;19:100292. DOI
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity & Metabolism, 2017;19(9):1242–1251. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Weight & Metabolism | Evidence Index: semaglutide · tirzepatide
Sources
- What Is Food Noise? A Conceptual Model of Food Cue Reactivity
- Nutrients, 2023 · DOI
- Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey
- Advances in Therapy, 2026 · n=550 · DOI
- The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior
- Physiology & Behavior, 2026 · n=79 · DOI
- Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
- Obesity, 2023 · n=174 · DOI
- Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study
- Obesity Pillars, 2026 · n=28 · DOI
- Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
- Diabetes, Obesity & Metabolism, 2017 · n=30 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.